Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
Lancet Oncol
    April 2024
  1. VAN DER VOORT A, Louis FM, van Ramshorst MS, Kessels R, et al
    MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II-III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study.
    Lancet Oncol. 2024 Apr 5:S1470-2045(24)00104.
    >> Share

  2. BROWNE IM, Andre F, Chandarlapaty S, Carey LA, et al
    Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
    Lancet Oncol. 2024;25:e139-e151.
    >> Share

  3. LAYMAN RM, Han HS, Rugo HS, Stringer-Reasor EM, et al
    Gedatolisib in combination with palbociclib and endocrine therapy in women with hormone receptor-positive, HER2-negative advanced breast cancer: results from the dose expansion groups of an open-label, phase 1b study.
    Lancet Oncol. 2024;25:474-487.
    >> Share

    March 2024
  4. TOI M, Kinoshita T, Benson JR, Jatoi I, et al
    Non-surgical ablation for breast cancer: an emerging therapeutic option.
    Lancet Oncol. 2024;25:e114-e125.
    >> Share

    February 2024
  5. PALMIERI C, Linden H, Birrell SN, Wheelwright S, et al
    Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multin
    Lancet Oncol. 2024 Feb 8:S1470-2045(24)00004.
    >> Share

  6. CHEN N, Nanda R
    Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer.
    Lancet Oncol. 2024 Feb 8:S1470-2045(24)00080.
    >> Share

  7. MEATTINI I, Becherini C, Caini S, Coles CE, et al
    International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
    Lancet Oncol. 2024;25:e73-e83.
    >> Share

  8. BAJPAI J, Kapu V, Rath S, Kumar S, et al
    Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled,
    Lancet Oncol. 2024;25:246-254.
    >> Share

    January 2024
  9. OKINES A, Turner N
    Developing therapies for triple-negative breast cancer subtypes.
    Lancet Oncol. 2024 Jan 8:S1470-2045(23)00639.
    >> Share

  10. FAN L, Wang ZH, Ma LX, Wu SY, et al
    Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial.
    Lancet Oncol. 2024 Jan 8:S1470-2045(23)00579.
    >> Share

  11. CHUMSRI S
    Serum hormone concentrations and individualisation of breast cancer prevention.
    Lancet Oncol. 2024;25:8-9.
    >> Share

    December 2023
  12. THE EDITORS OF THE LANCET ONCO
    Expression of concern-Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
    Lancet Oncol. 2023 Dec 21:S1470-2045(23)00673.
    >> Share

  13. CUZICK J, Chu K, Keevil B, Brentnall AR, et al
    Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
    Lancet Oncol. 2023 Dec 5:S1470-2045(23)00578.
    >> Share

  14. THE LANCET ONCOLOGY
    Breast cancer screening: one size does not fit all.
    Lancet Oncol. 2023;24:1287.
    >> Share

    November 2023
  15. VELIKOVA G, Morden JP, Haviland JS, Emery C, et al
    Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomis
    Lancet Oncol. 2023 Nov 2:S1470-2045(23)00460.
    >> Share

  16. HORINO T
    Retroperitoneal metastasis of breast cancer misdiagnosed as retroperitoneal fibrosis.
    Lancet Oncol. 2023;24:e451.
    >> Share

    September 2023
  17. XU B
    Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy - Author's reply.
    Lancet Oncol. 2023;24:e357.
    >> Share

  18. HINDIE E
    Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy.
    Lancet Oncol. 2023;24:e356.
    >> Share

  19. TOI M, Aruga T
    SERDs for primary breast cancer.
    Lancet Oncol. 2023;24:947-949.
    >> Share

  20. HURVITZ SA, Bardia A, Quiroga V, Park YH, et al
    Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
    Lancet Oncol. 2023;24:1029-1041.
    >> Share

    August 2023
  21. PASQUIER D, Bidaut L, Oprea-Lager DE, deSouza NM, et al
    Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.
    Lancet Oncol. 2023;24:e331-e343.
    >> Share

  22. LANG K, Josefsson V, Larsson AM, Larsson S, et al
    Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening
    Lancet Oncol. 2023;24:936-944.
    >> Share

  23. SEGNAN N, Ponti A
    Artificial intelligence for breast cancer screening: breathtaking results and a word of caution.
    Lancet Oncol. 2023;24:830-832.
    >> Share

    June 2023
  24. CHEN X, Shen K
    Dalpiciclib in advanced breast cancer.
    Lancet Oncol. 2023;24:578-579.
    >> Share

  25. HUNTLEY C, Torr B, Sud A, Rowlands CF, et al
    Utility of polygenic risk scores in UK cancer screening: a modelling analysis.
    Lancet Oncol. 2023;24:658-668.
    >> Share

    May 2023
  26. VENKATESAN P
    New US breast cancer screening recommendations.
    Lancet Oncol. 2023 May 18:S1470-2045(23)00238.
    >> Share

  27. ZHANG P, Zhang Q, Tong Z, Sun T, et al
    Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo
    Lancet Oncol. 2023 May 11:S1470-2045(23)00172.
    >> Share

  28. MEIRSON T, Goldstein DA, Gyawali B, Tannock IF, et al
    Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer.
    Lancet Oncol. 2023 May 2:S1470-2045(23)00165.
    >> Share

  29. JOHNSTON SRD, Tolaney SM, O'Shaughnessy J, Rastogi P, et al
    Review of the monarchE trial suggests no evidence to support use of adjuvant abemaciclib in women with breast cancer - Authors' reply.
    Lancet Oncol. 2023 May 2:S1470-2045(23)00214.
    >> Share

    April 2023
  30. BEHROOZIAN T, Bonomo P, Patel P, Kanee L, et al
    Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations.
    Lancet Oncol. 2023;24:e172-e185.
    >> Share

    March 2023
  31. WU S, Hong G, Xu A, Zeng H, et al
    Artificial intelligence-based model for lymph node metastases detection on whole slide images in bladder cancer: a retrospective, multicentre, diagnostic study.
    Lancet Oncol. 2023 Mar 6:S1470-2045(23)00061.
    >> Share

  32. JOHNSTON SRD, Andre V
    Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer - Authors' reply.
    Lancet Oncol. 2023;24:e104.
    >> Share

  33. NOZAWA K, Sawaki M, Iwata H
    Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer.
    Lancet Oncol. 2023;24:e103.
    >> Share

  34. TOLANEY SM, Tarantino P, Graham N, Tayob N, et al
    Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
    Lancet Oncol. 2023;24:273-285.
    >> Share

  35. GEUNA E, Curigliano G, Montemurro F
    De-escalation in low-risk, HER2-positive breast cancer.
    Lancet Oncol. 2023;24:200-201.
    >> Share

    February 2023
  36. CHATTERJI S, Krzoska E, Thoroughgood CW, Saganty J, et al
    Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.
    Lancet Oncol. 2023;24:e74-e85.
    >> Share

  37. STRNAD V, Polgar C, Ott OJ, Hildebrandt G, et al
    Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial.
    Lancet Oncol. 2023 Feb 1:S1470-2045(23)00018.
    >> Share

    January 2023
  38. RODLER E, Sharma P, Barlow WE, Gralow JR, et al
    Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Oncol. 2023 Jan 6:S1470-2045(22)00739.
    >> Share

  39. HU X, Fujiwara T, Sun Y, Huang W, et al
    Treatment-related thoracic soft tissue sarcomas in survivors of breast cancer.
    Lancet Oncol. 2023;24:e6.
    >> Share

  40. GARCIA-PELAEZ J, Barbosa-Matos R, Lobo S, Dias A, et al
    Genotype-first approach to identify associations between CDH1 germline variants and cancer phenotypes: a multicentre study by the European Reference Network on Genetic Tumour Risk Syndromes.
    Lancet Oncol. 2023;24:91-106.
    >> Share

    December 2022
  41. JOHNSTON SRD, Toi M, O'Shaughnessy J, Rastogi P, et al
    Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
    Lancet Oncol. 2022 Dec 5:S1470-2045(22)00694.
    >> Share

  42. SPANHEIMER PM, Reeder-Hayes KE
    Breast surgery after neoadjuvant chemotherapy: time for a change?
    Lancet Oncol. 2022;23:1477-1479.
    >> Share

    November 2022
  43. DEL MASTRO L, Poggio F, Blondeaux E, De Placido S, et al
    Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.
    Lancet Oncol. 2022 Nov 9. pii: S1470-2045(22)00632.
    >> Share

  44. MORGANTI S, Tolaney SM
    Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trial.
    Lancet Oncol. 2022 Nov 9. pii: S1470-2045(22)00685.
    >> Share

  45. BENARD F, Harsini S, Wilson D, Zukotynski K, et al
    Intra-individual comparison of (18)F-sodium fluoride PET-CT and (99m)Tc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.
    Lancet Oncol. 2022 Nov 4. pii: S1470-2045(22)00642.
    >> Share

    October 2022
  46. KUERER HM, Smith BD, Krishnamurthy S, Yang WT, et al
    Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial.
    Lancet Oncol. 2022 Oct 25. pii: S1470-2045(22)00613.
    >> Share

  47. VEIGA LHS, Vo JB, Curtis RE, Mille MM, et al
    Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study.
    Lancet Oncol. 2022 Oct 11. pii: S1470-2045(22)00561.
    >> Share

  48. RUGO HS, Singer L
    First, do no harm: risk of secondary cancer after breast cancer treatment.
    Lancet Oncol. 2022 Oct 11. pii: S1470-2045(22)00627.
    >> Share

    September 2022
  49. BIDARD FC, Hardy-Bessard AC, Dalenc F, Bachelot T, et al
    Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
    Lancet Oncol. 2022 Sep 29. pii: S1470-2045(22)00555.
    >> Share

    August 2022
  50. KIROVA Y, Loap P
    Customising radiotherapy in stage II breast cancer after primary chemotherapy.
    Lancet Oncol. 2022 Aug 8. pii: S1470-2045(22)00496.
    >> Share

  51. DE WILD SR, de Munck L, Simons JM, Verloop J, et al
    De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study.
    Lancet Oncol. 2022 Aug 8. pii: S1470-2045(22)00482.
    >> Share

  52. HEINDEL W, Weigel S, Hense HW
    Surrogate endpoints in breast cancer screening trials - Authors' reply.
    Lancet Oncol. 2022;23:e361.
    >> Share

  53. JATOI I
    Surrogate endpoints in breast cancer screening trials.
    Lancet Oncol. 2022;23:e360.
    >> Share

    July 2022
  54. TERAN E, Gomez H, Hannois D, Lema M, et al
    Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective.
    Lancet Oncol. 2022;23:e348-e358.
    >> Share

  55. KRISTELEIT R, Oza AM
    Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations - Authors' reply.
    Lancet Oncol. 2022;23:e315.
    >> Share

  56. GANGULY S, Gogia A
    Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations.
    Lancet Oncol. 2022;23:e314.
    >> Share

  57. JOSEPH JP, Bhangdia K, Damuse R, Lormil J, et al
    Impact of geospatial barriers on breast cancer care in Haiti: a retrospective cohort study.
    Lancet Oncol. 2022;23 Suppl 1:S40.
    >> Share

  58. VIDAURRE T, Enriquez-Vera D, Bertani S
    Excess mortality in patients with cancer during the COVID-19 pandemic in Peru: an analysis of death registry data.
    Lancet Oncol. 2022;23 Suppl 1:S28.
    >> Share

  59. HOMMA MK, Hashimoto Y, Homma Y, Nomizu T, et al
    CK2alpha as a prognostic factor in invasive ductal carcinomas of the breast: cancer recurrence prognosis by surgical sampling.
    Lancet Oncol. 2022;23 Suppl 1:S25.
    >> Share

  60. RAMPRASAD J, Krishnan L, Gangadharan C, Deshpande G, et al
    Performance of artificial intelligence-based breast cancer screening in a community setting: a real-world evaluation study.
    Lancet Oncol. 2022;23 Suppl 1:S20.
    >> Share

  61. YADAV B, Rana D, Bharti D, Dahiya D, et al
    Impact of COVID-19 pandemic on breast cancer care: report from a regional cancer centre.
    Lancet Oncol. 2022;23 Suppl 1:S17.
    >> Share

    June 2022
  62. HOWELL SJ, Casbard A, Carucci M, Ingarfield K, et al
    Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded bi
    Lancet Oncol. 2022 Jun 1. pii: S1470-2045(22)00284.
    >> Share

  63. BRAY F, Parkin DM
    Cancer in sub-Saharan Africa in 2020: a review of current estimates of the national burden, data gaps, and future needs.
    Lancet Oncol. 2022;23:719-728.
    >> Share

    May 2022
  64. FOERSTER M, McCormack V, Anderson BO, Boucheron P, et al
    Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study.
    Lancet Oncol. 2022 May 9. pii: S1470-2045(22)00198.
    >> Share

  65. GOURD E
    Philippa Kibugu-Decuir-founder of Breast Cancer Initiative East Africa.
    Lancet Oncol. 2022 May 9. pii: S1470-2045(22)00249.
    >> Share

  66. YAN M
    Screening for breast cancer brain metastases - Authors' reply.
    Lancet Oncol. 2022;23:e201.
    >> Share

  67. KNISELY J
    Screening for breast cancer brain metastases.
    Lancet Oncol. 2022;23:e200.
    >> Share

    April 2022
  68. HOUSSAMI N
    Should tomosynthesis replace mammography for breast cancer screening?
    Lancet Oncol. 2022 Apr 12. pii: S1470-2045(22)00215.
    >> Share

  69. HEINDEL W, Weigel S, Gerss J, Hense HW, et al
    Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): a multicentre, open-label, randomised, controlled, superiority trial.
    Lancet Oncol. 2022 Apr 12. pii: S1470-2045(22)00194.
    >> Share

  70. NITZ U, Gluz O, Graeser M, Christgen M, et al
    De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase
    Lancet Oncol. 2022 Apr 8. pii: S1470-2045(22)00159.
    >> Share

  71. SAJI S, Taira N, Kitada M, Takano T, et al
    Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
    Lancet Oncol. 2022 Apr 8. pii: S1470-2045(22)00196.
    >> Share

  72. QUESADA S, Jacot W
    Maintenance endocrine therapy plus bevacizumab for advanced or metastatic breast cancer.
    Lancet Oncol. 2022 Apr 8. pii: S1470-2045(22)00205.
    >> Share

  73. THIRUCHELVAM PTR, Leff DR, Godden AR, Cleator S, et al
    Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): a multicentre, prospective, non-randomised, feasibility study.
    Lancet Oncol. 2022 Apr 7. pii: S1470-2045(22)00145.
    >> Share

    March 2022
  74. BECERRA-CHAUCA N, Nieto-Gutierrez W, Taype-Rondan A
    6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting.
    Lancet Oncol. 2022;23:e100.
    >> Share

  75. DROUIN E, Classe JM, Hautecoeur P
    Sentinel nodes and breast cancer: an old story.
    Lancet Oncol. 2022;23:340.
    >> Share

  76. ANTONARELLI G, Valenza C, Mayer EL, Loibl S, et al
    Cyclin dependent kinase 4/6 inhibitors in early breast cancer: what is the role of Ki-67?
    Lancet Oncol. 2022;23:325-328.
    >> Share

    February 2022
  77. TRIUNFOL M
    IAEA and Brazilian Navy to provide new arsenal to fight breast cancer: mammography on a ship.
    Lancet Oncol. 2022 Feb 17. pii: S1470-2045(22)00093.
    >> Share


  78. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.
    Lancet Oncol. 2022 Feb 3. pii: S1470-2045(21)00758.
    >> Share

  79. FEYAERTS A, Demey W
    Bone marrow invasion in breast carcinoma.
    Lancet Oncol. 2022;23:e88.
    >> Share

  80. DEVI S
    MSF breast and cervical cancer screening programmes in Mali and Malawi.
    Lancet Oncol. 2022;23:207-208.
    >> Share

    January 2022
  81. YAN M, Ouyang Q, Sun T, Niu L, et al
    Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial.
    Lancet Oncol. 2022 Jan 24. pii: S1470-2045(21)00716.
    >> Share

  82. BAILLEUX C, Bachelot T
    Medical treatment for active breast cancer brain metastases.
    Lancet Oncol. 2022 Jan 24. pii: S1470-2045(22)00022.
    >> Share

  83. FOWLER AM, Strigel RM
    Clinical advances in PET-MRI for breast cancer.
    Lancet Oncol. 2022;23:e32-e43.
    >> Share

  84. MEATTINI I, Becherini C, Boersma L, Kaidar-Person O, et al
    European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer.
    Lancet Oncol. 2022;23:e21-e31.
    >> Share

    December 2021
  85. REEVES C
    San Antonio Breast Cancer Symposium 2021.
    Lancet Oncol. 2021 Dec 16. pii: S1470-2045(21)00727.
    >> Share

  86. YAU C, Osdoit M, van der Noordaa M, Shad S, et al
    Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients.
    Lancet Oncol. 2021 Dec 10. pii: S1470-2045(21)00589.
    >> Share

    November 2021
  87. XIE Y, Mata DGMM, Huang WY, Djordjevic B, et al
    A growing vulvar mass in a post-menopausal woman.
    Lancet Oncol. 2021;22:e530.
    >> Share

    October 2021
  88. GAO JJ, Cheng J, Prowell TM, Bloomquist E, et al
    Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
    Lancet Oncol. 2021 Oct 14. pii: S1470-2045(21)00472.
    >> Share

  89. HEER E
    Addressing breast cancer mortality in low-income and middle-income countries: if you can't measure it, it doesn't exist.
    Lancet Oncol. 2021 Oct 12. pii: S1470-2045(21)00519.
    >> Share

  90. DUGGAN C, Trapani D, Ilbawi AM, Fidarova E, et al
    National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population-based analysis.
    Lancet Oncol. 2021 Oct 12. pii: S1470-2045(21)00462.
    >> Share

  91. DENKERT C, Nekljudova V, Loibl S
    HER2-low-positive breast cancer from four neoadjuvant clinical trials - Authors' reply.
    Lancet Oncol. 2021;22:e427.
    >> Share

  92. OMAR A, Arafat W
    HER2-low-positive breast cancer from four neoadjuvant clinical trials.
    Lancet Oncol. 2021;22:e426.
    >> Share

  93. MANO MS
    Patient-accessible test reports in times of instant messaging communication: progress or an additional emotional burden?
    Lancet Oncol. 2021;22:1365-1366.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016